BR112016009572A2 - Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo - Google Patents

Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo

Info

Publication number
BR112016009572A2
BR112016009572A2 BR112016009572A BR112016009572A BR112016009572A2 BR 112016009572 A2 BR112016009572 A2 BR 112016009572A2 BR 112016009572 A BR112016009572 A BR 112016009572A BR 112016009572 A BR112016009572 A BR 112016009572A BR 112016009572 A2 BR112016009572 A2 BR 112016009572A2
Authority
BR
Brazil
Prior art keywords
human relaxin
pharmaceutical
pharmaceutical composition
relaxin analog
applications
Prior art date
Application number
BR112016009572A
Other languages
English (en)
Inventor
Zhang Lianshan
Liu Jiajian
Cao Guoqing
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of BR112016009572A2 publication Critical patent/BR112016009572A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

ANÁLOGO DE RELAXINA HUMANA, COMPOSIÇÃO FARMACÊUTICA DO MESMO E APLICAÇÃO FARMACÊUTICA DO MESMO. A presente invenção refere-se a um análogo de relaxina humana, um polinucleotídeo para codificar o análogo de relaxina humana, uma composição farmacêutica do análogo de relaxina humana e uma aplicação farmacêutica do análogo de relaxina humana. Um derivado do análogo de relaxina humana é adicionalmente descrito.
BR112016009572A 2013-11-07 2014-10-10 Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo BR112016009572A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310548221 2013-11-07
PCT/CN2014/088280 WO2015067113A1 (zh) 2013-11-07 2014-10-10 人松驰素类似物、其药物组合物及其在医药上的应用

Publications (1)

Publication Number Publication Date
BR112016009572A2 true BR112016009572A2 (pt) 2017-09-19

Family

ID=53040882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009572A BR112016009572A2 (pt) 2013-11-07 2014-10-10 Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo

Country Status (13)

Country Link
US (1) US20160326230A1 (pt)
EP (1) EP3067365A1 (pt)
JP (1) JP2016536306A (pt)
KR (1) KR20160071472A (pt)
CN (1) CN104870470B (pt)
AU (1) AU2014346141A1 (pt)
BR (1) BR112016009572A2 (pt)
CA (1) CA2928754A1 (pt)
HK (1) HK1211594A1 (pt)
MX (1) MX2016005545A (pt)
RU (1) RU2016117959A (pt)
TW (1) TW201518319A (pt)
WO (1) WO2015067113A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007822A (zh) * 2016-01-27 2017-08-04 江苏恒瑞医药股份有限公司 一种含有重组人松弛素‑2类似物的药物组合物及其制备方法
CN107417787B (zh) * 2016-05-23 2020-11-17 江苏恒瑞医药股份有限公司 一种人松弛素2类似物的制备方法
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW202120536A (zh) * 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20070202080A1 (en) * 2004-03-30 2007-08-30 Industry-University Cooperation Foundation Yonsei Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin
MX336145B (es) * 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
CN102180964B (zh) * 2011-03-16 2013-06-05 济南环肽医药科技有限公司 一种人类松弛素-2 Relaxin的固相合成方法
CN102603888B (zh) * 2012-04-11 2013-11-20 黑龙江八一农垦大学 一种人松弛素2前体及其制备方法

Also Published As

Publication number Publication date
KR20160071472A (ko) 2016-06-21
JP2016536306A (ja) 2016-11-24
TW201518319A (zh) 2015-05-16
AU2014346141A1 (en) 2016-05-19
HK1211594A1 (en) 2016-05-27
EP3067365A1 (en) 2016-09-14
US20160326230A1 (en) 2016-11-10
MX2016005545A (es) 2016-10-03
CA2928754A1 (en) 2015-05-14
CN104870470B (zh) 2017-10-10
RU2016117959A (ru) 2017-12-11
CN104870470A (zh) 2015-08-26
WO2015067113A1 (zh) 2015-05-14

Similar Documents

Publication Publication Date Title
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CL2016000873A1 (es) Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento.
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
FR3021533B1 (fr) Composition cosmetique de type gel
FR3002449B1 (fr) Composition cosmetique de type gel
BR112015028290A2 (pt) composições e processos para entrega tópica de prostaglandinas à gordura subcutânea
BR112016021011A2 (pt) composição tópica e usos de um composto
FR3004343B1 (fr) Composition cosmetique de type gel
SV2016005230A (es) Derivados de acido heteroaril butanoico como inhibidores de lta4h
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
GT201500247A (es) Imidazopiridazinas sustituidas
HK1217443A1 (zh) 用於糖尿病的口服治療的藥物組合物
BR112016008736A2 (pt) formulação estável de insulina glulisina
BR112015019578A2 (pt) composição para uso farmacêutico com atividade antioxidante contra radicais livres, uso cosmético de uma composição para produzir atividade antioxidante contra radicais livres e uso nutricional dietético de uma composição para produzir atividade antioxidante contra radicais livres
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
DK2988733T3 (da) Farmaceutisk sammensætning indeholdende krystallin macitentan
BR112016009572A2 (pt) Análogo de relaxina humana, composição farmacêutica do mesmo e aplicação farmacêutica do mesmo
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
EP2966087A4 (en) ANTIBODY TO A PEPTIDE CODED BY EXON-21 OF PERIOSTIN, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASE CONTAINING SAID ANTIBODY
BR112016021835A8 (pt) análogo cíclico da apelina de fórmula geral x1-x2-x3-x4-x5-x6-x7-x8-x9-x10-x11-x12-x13-x14, composição farmacêutica, e método para proporcionar um análogo da apelina
FR3025098B1 (fr) Composition cosmetique de type gel facilement demaquillable
BR112015002726A8 (pt) combinação, composição farmacêutica, kit, e, usos de uma combinação, e de uma composição farmaceutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]